G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

November 2, 2022

https://www.globenewswire.com/news-release/2022/11/02/2546276/0/en/G1-Therapeutics-Provides-Third-Quarter-2022-Financial-Results-and-Operational-Highlights.html

– Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) –

– Provided Encouraging Initial Data from Phase 2 Trial Demonstrating Potential of Trilaciclib to Reduce (>50%) the Rates of Adverse Events (AEs) Related to an Antibody-Drug Conjugate (ADC) –

Read more at globenewswire.com

Related news for (GTHX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.